Haleon

HLN

Market cap $43.5B

Viral mega-creator Airrack joins the brand for a playful campaign featuring trick shots, social sweepstakes and heartburn relief that's passable WARREN, N.J., Jan. 6, 2026 /PRNewswire/ -- One in four Big Game watchers experience occasional heartburn from their favorite foods — and 75% of those fans are unprepared, without relief on hand*.

WARREN, N.J.--(BUSINESS WIRE)--Haleon, a global leader in consumer health, today announced it has been honored in Fast Company's 2025 Brands That Matter list in the Family of Brands category, which highlights companies that created cultural moments for multiple brands across their portfolios. The annual list recognizes organizations that demonstrate cultural relevance, meaningful consumer connection, and a clear commitment to purpose. “We are incredibly proud to be recognized by Fast Company fo.

Haleon (HLN) remains a solid consumer goods company, with strong brands like Sensodyne, but growth is incremental and largely price-driven. HLN's recent results show modest organic revenue growth, with volume gains limited and most categories outside oral health underperforming. The company's full-year organic revenue guidance is around 3.5%, but risks from subdued consumer demand and, over the longer term, limited innovation persist.

Overseas Equity ETF posted a return of 7.27% in the third quarter of 2025. Leading contributors in the First Eagle Overseas Equity ETF this quarter included Samsung Electronics Co Ltd Pfd Non-Voting, Alibaba Group, Barrick Mining, Newmont and Prosus N.V. Class N. The leading detractors in the quarter were Shimano, FUCHS SE Pref Registered Shs, SMC Corporation, Haleon and Philip Morris.

Haleon PLC's (LSE:HLN, NYSE:HLN) third-quarter numbers were in line with expectations and the outlook was maintained, but analysts at Barclays flagged that the toothpaste, painkiller and vitamin maker is not yet out of the woods.  Organic sales growth (OSG) of 3.4% for the quarter was in line with the average analyst forecast, helped by better volumes, though the Oral Health arm saw growth short of the City consensus.

Haleon plc ( HLN ) Q3 2025 Sales Call October 30, 2025 5:00 AM EDT Company Participants Joanne Russell - Head of Investor Relations Dawn Allen - CFO & Director Conference Call Participants Guillaume Gerard Delmas - UBS Investment Bank, Research Division Olivier Nicolai David Hayes - Jefferies LLC, Research Division Jeremy Fialko - HSBC Global Investment Research Celine Pannuti - JPMorgan Chase & Co, Research Division Karel Zoete - Kepler Cheuvreux, Research Division Mikheil Omanadze - BNP Paribas Exane, Research Division Tom Sykes - Deutsche Bank AG, Research Division Warren Ackerman - Barclays Bank PLC, Research Division Edward Lewis - Rothschild & Co Redburn, Research Division Presentation Operator Good morning. Thank you for attending today's Haleon 2025 Quarter 3 Trading Statement.

Haleon PLC (LSE:HLN, NYSE:HLN) delivered a slight improvement in organic revenue growth of 3.4% in the third quarter and maintained its full-year guidance. The maker of Sensodyne, Panadol and Centrum saw top-line expansion pick up from 3.0% in the second quarter.

British consumer healthcare group Haleon reported third-quarter organic revenue growth marginally above market estimates on Thursday, helped by strong demand for its oral health products.

The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecutive quarter of double-digit revenue and profit growth. Japan was the largest detractor, with Chugai and Sysmex weighing on results.

The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.